WEBINAR -February 18, 2021 from 12:00 pm - 1:00 pm
**Registration for this event is now closed. If you have any questions, please contact the office by calling (781) 647-4773 or emailing email@example.com.**
In 2019, after many years of new guidance updates (which include ASTM E2500, ICH Q8, Q9, 10, as well as FDA Guidance for industry), ISPE updated its paramount baseline guide for Commissioning and Qualification.
The purpose of this updated guidance is to define the Baseline® approach for the Commissioning and Qualification of facilities, utilities, and equipment regulated by the FDA. This will assist in optimizing the commissioning and qualification processes at regulated facilities.
Despite this monumental effort, adoption in industry by end users is slow at best, and has not been widely accepted. These presentations, and breakout panel discussions by the speakers, will address challenges in adopting the updated methodology, and will also include how to manage change to encourage adoption. The discussion will also include testimonials directly from end users, and show how adoption can lead to more integrated qualification approach, allowing for faster project turnaround and cost savings.
Michael Polansky, Director, Corporate Quality, AstraZeneca
As a Director of Corporate Quality at AstraZeneca, Mike is the Quality Process Champion for Premises and Equipment, functioning as the primary Quality liaison with Global Engineering in the development of Engineering standards and improved quality focus of Engineering processes. Prior to working in Corporate Quality, Mike was the site lead of Quality Systems and Compliance at AstraZeneca’s biopharmaceutical bulk manufacturing facility in Frederick, MD. Over his 23 years of pharmaceutical industry experience, Mike has also held various Quality and CQV roles at Sanofi Pasteur, Centocor, Inc. (now Janssen Biotech) and GlaxoSmithKline. During his tenure at Sanofi Pasteur, Mike was responsible for the successful program development of Integrated Commissioning and Qualification, under the site Engineering function, as the Director of Commissioning and Qualification Best Practices.
Deborah Wild, President, DW BioPharma
Deborah Wild is the President of DW BioPharma and was previously Chief of Staff/Head Global Cell and Gene Therapy Business management for Catalent, Cell and Gene Therapy. Deb is an accomplished C-Suite Executive with over 30 years’ experience and has effectively lead large groups that include Quality Assurance, Quality Control, Validation, Regulatory Affairs, and Manufacturing departments throughout her career. Deb was a key executive team member that transitioned a family owned business into a hyper growth Private Equity (PE) backed success, resulting in a $1.2B purchase by Catalent in 2019, delivering record returns for PE investment partners. She is a biotechnology and pharmaceutical leader with a proven record in bringing products to market and an entrepreneur’s perspective as an owner of a successful consulting business.
WHO SHOULD ATTEND THIS WEBINAR:
This program is geared towards professionals interested in general equipment facilities validation.
PROGRAM FEES: Member: FREE Student Member: FREE Young Professional Member: FREE Non-Member: $15
Registration Deadline is Wednesday, February 17th at 5:00 pm.
LOG ON INFORMATION: Prior to the webinar a confirmation e-mail will be sent with the Zoom information. The webinar can be accessed through phone, online, or through the Zoom webinar app.
MEETING MANAGERS: Michael Bogan, ICQ Consultants, Corp.